CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O.

sufficient postage as first class mail in an envelope addressed to: C. Box 1450, Alexandria, VA 22313-1450, on

TECH CENTER PODE SOO

Attorney Docket No. 39750-0001A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Daniel Erlanson, et al.

Application No.: 09/990,421

Filed: November 21, 2001

Title: Extended Tethering Approach for Rapid

Identification of Ligands

PATENT APPLICATION

Art Unit: 1626

Examiner: To Be Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

-1-

\boxtimes	This sta	tement (qualifies under <i>37 C.F.R</i> . <i>§1.97</i> , s	subsection (b) because (check all that apply):			
		(1)	It is being filed within 3 months continued prosecution application OR	of the application filing date and is other than a on under § 1.53(d)			
		(2)	It is being filed within 3 months OR	of entry of a national stage			
	\boxtimes	(3)	It is being filed before the mail of OR	date of the first Office Action on the merits			
		(4)	It is being filed before the mailing for continued examination under	ng of a first Office Action after the filing of a request r § 1.114.			
	filing d set forti merits,	ate of a h in §1.4 but befo	national application; (2) three mo	ed after the latest of: (1) three months beyond the onths beyond the date of entry of the national stage as n; or (3) the mailing date of a first Office action on the of a final office action under §1.113 or a notice of			
		a certif	ication as specified in §1.97(e) is	provided below; or			
		a fee of	f \$180.00 as set forth in §1.17(p) nt of other papers filed together v	is authorized below, enclosed, or included with the with this statement.			
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:						
	Α.	a certification as specified in §1.97(e) is completed below; and					
	В.		on under 37 C.F.R. §1.97(d) requ th; and	nesting consideration of this statement is submitted			
	Ç.	a fee or	f \$130.00 as set forth in §1.17(i)(nt of other papers filed together v	1) is authorized below, enclosed, or included with the with this statement.			
	\$0.00 a	nd char	ion. The Commissioner is hereby ge any additional fees or credit and nt No. 08-1641 (Docket No. 397)	y authorized to charge the above-referenced fees of ny overpayment associated with this communication to 50-0001A).			
				Respectfully submitted,			
			•	HELLER EHRMAN WHITE & MCAULIFFE LLP			
Dated:	Ju	ly 15	5, 2003	By: Saon L. Nguyễn, Reg. No. 52,496			
Menlo (650) 3	ddlefiel Park, Ca 24-7000 ner No. 2	A 94025)	-3506				

-2-

SHEET 1OF 3

						SHEE			
INFORMATION DISCLOSURE			ATTY. DOCKET NO. 39750-0001A	i	RIAL NO. 990,421				
			APPLICANT Daniel Erlanson, et al.						
JUL 2 1 2003	PTO-1449		FILING DATE November 21, 2001	GR	OUP: 1626				
& TRAUCE	-	U.S	S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING	DATE		
JE	5,367,058	11/22/94	Pitner, et al.	530	391.9				
		FOR	EIGN PATENT DOCUMENT	`S					
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION		
INITIALS		<u> </u>				YES	NO		
					-				
	OTHER DO	CUMENTS	(Including Author, Title, Date,	Pertinent P	ages, Etc.)				
						2			
				•	<u> </u>	<u>``C`, </u>			
					و ا	1/2			
					To	1 Co	〉		
					100	~			
					7.00	2			
				11.	1		 		
EXAMINER	12 1		DATE CONSIDERED	<u> </u>	1 AY				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK

Applicant	:	Erlanson et al.) Group Art Unit 1626
)
App. No.	:	09/990,421)

Filed: November 21, 2001

For : AN EXTENDED)

TETHERING APPROACH FOR RAPID

IDENTIFICATION OF

LIGANDS

Examiner : Unknown

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 1 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: Odeal Sypt atter

Adeel S. Akhtar
Registration No. 41,394
Attorney of Record
620 Newport Center Drive
Sixteenth Floor

Newport Beach, CA 92660

(415) 954-4114

W:\DOCS\GRD\GRD-8393.DOC071102W:\DOCS\GRD\GRD-8393.DOC071102

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT

IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ţ



NTITE ON THE STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Erlanson et al.	.)	Group Art Unit 162
App. No.	:	09/990,421)	

Filed: November 21, 2001

For : AN EXTENDED

THETHERING APPROACH

FOR RAPID

IDENTIFICATION OF

LIGANDS

Examiner : Unknown

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing 48 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 24, 2002 By: Ginger R. Dreger

Registration No. 33,055
Attorney of Record
620 Newport Center Drive

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(415) 954-4114

W:\DOC\$\GRD\GRD-7181.DOC011002

			SHEET 1	OF 3
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. SUNESIS.001A	APPLICATION NO. 09/990,421	AF TECH O	7
FEB 1 3 2002	APPLICANT Erlanson, et al.		ENTER	d
(USE SAVERAL SHEETS IF NECESSARY)	FILING DATE November 21, 2001	GROUP 1638	8 200 8 1600	₹
TANKAR			229	
			0	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
JE	1.	4,946,778	8/7/90	Ladner et al.	435	69.6	
}	2.	5,422,281	6/6/95	Harris et al.	436	501	
7	3.	5,571,681	11/5/96	Janda	435	7.6	
1	4.	5,783,384	7/21/98	Verdine	535	6	
U	5.	5,958,702	9/28/99	Benner	435	7.1	
	\sqcup						
					1		

FOREIGN PATENT DOCUMENTS											
EXAMINER	DOCUMENT NUMBER DATE COUNTRY		COUNTRY	CLASS	SUBCLASS	TRANS	LATION				
INITIAL					<u> </u>		YES	NO			
725	6.	EP 0 801 307	10/15/97	EP							
7	7.	WO 95/18972	7/13/95	PCT							
	8.	WO 95/25737	9/28/95	РСТ							
	9.	WO 96/13613	5/9/96	РСТ			·				
	10.	WO 96/27605	9/12/96	РСТ .							
	11.	WO 97/12897	4/10/97	РСТ							
	12.	WO 97/35202	11/20/97	РСТ							
	13.	WO 97/43302	11/20/97	РСТ							
	14.	WO 98/11436	3/19/98	РСТ							
	15.	WO 98/11437	3/19/98	РСТ							
	16.	WO 98/15969	4/16/98	PCT							
Ø	17.	WO 98/25146	6/11/98	РСТ							

EXAMINER (r 4	DATE CONSIDERED 6 // Oc/
*EXAMINER: INITIAL IN CONFORMANCE	L IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH	S IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT H NEXT COMMUNICATION TO APPLICANT.

× >				#	SHEET.	-2√⊝ F3
•	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SUNESIS.001A	APPLICATION NO. 09/990,421	OH CEN	हिल्प	REC.
	3	APPLICANT Erlanson, et al.		TER 16	39 70	Z
	(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE November 21, 2001	GROUP 1638	00/29 00	02	

	FOREIGN PATENT DOCUMENTS										
EXAMINER		DOCUMENT NUMBER	OCUMENT NUMBER DATE COUNTRY	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
INITIAL							YES	NO			
72	18.	WO 98/56028	12/10/98	РСТ							
1	19.	WO 99/50668	10/07/99	PCT							
1	20.	WO 99/50669	10/7/99	РСТ							
	21.	WO 99/63944	12/16/99	РСТ							
	22.	WO 00/00823	1/6/00	РСТ							
1	23.	WO 00/03240	1/20/00	PCT							
d	24.	WO 01/02856	1/11/01	РСТ							

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
76	25.	Abraham, D.J. et al., "How Allosteric Effectors Can Bind to the Same Protein Residue and Produce Opposite Shifts in the Allosteric Equilibrium" <u>Biochemistry</u> 34:150006-15020 (1995)
	26.	Boyiri, T. et al., "Bisaldehyde Allosteric Effectors as Molecular Ratchets and Probes" <u>Biochemistry</u> 34:15021-15036 (1995)
	27.	Bunyapaiboonsri et al., "Dynamic Deconvolution of a Pre-Equilibrated Dynamic Combinatorial Library of Acetylcholinesterase Inhibitors" ChemBioChem 2:438-444 (2001)
	28.	DeJarias et al., "Use of X-ray Co-crystal Structures and Molecular Modeling to Design Potent and Selective Non-peptide Inhibitors of Cathepsin K" J. Am. Chem. Soc. 120(35):9114-9115 (1998)
	29.	Erlanson et al., "Site-Directed ligand discovery" PNAS 97(17):9367-9372 (August 15, 2000)
	30.	Foroozesh et al. "Aryl Acetylenes as Mechanism-Based Inhibitors of Cytochrome P450-Dependent Monooxugenase Enzymes" Chem. Res. Toxicol. 10(1):91-102
	31.	Hopkins et al., "Suicide Inhibitor of Cytochrome P450 1A1 and P450 2B1" Biochem. Pharmacol. 44(4):787-796 (1992)
	32.	Huc and Lehn, "Virtual combinatorial libraries: Dynamic generation of molecular and supramolecular diversity by self-assembly" Proc. Natl. Acad. Sci. USA 94:2106-2110 (March 1997)
	33.	Jones and Thornton, "Principles of protein-protein interactions" Proc. Natl. Acad. Sci. USA 93:13-20 (January 1996)
	34.	Lehn, Jean-Marie, "Dynamic Combinatorial Chemistry and Virtual Combinatorial Libraries" Chem. Eur. J. 5(9)2455-2463 (1999)
d	35.	Maly et al., "Combinatorial target-guided ligand assembly: identification of potent sybtype-selective c-Src inhibitors" PNAS 97(6):2419-2424 (March 14, 2000)

	_/			,	
EXAMINER	In Co	DATE CONSIDERED	1/	10	
*EXAMINER: INITIAL	. IF CITATION CONSIDERED, WHETHER OR NOT CITATION OF THIS FOR	FION IS IN CONFORMANCE WITH	MPEP 609; D	RAW LI	NE THROUGH CITATION IF NOT

				SHEET	T 3 OF 3
•	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADECTED FRICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. SUNESIS.001A	09/990,421	APF	RE(
	BY APPLICANT FEB 1 3 2012	APPLICANT Erlanson, et al.	,	2 3	回
	(USE SEVERAL SHEETS IF NEW SSARY)	FILING DATE November 21, 2001	GROUP 1636	2002	J

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
K	36.	Mathews et al., "N-Alkylaminobenzotriazoles as Isozyme-Selective Suicide Inhibitors of Rabbit Pulmonary Microsomal Cytochrome P-450" Mol. Pharmacol. 39(10):25-32 (1986)
	37.	Misumi et al., "The p2 gag Peptide, AEAMSQVTNTATIM, Processed for HIC-1 Pr55 gag was found to be a Suicide Inhibitor of HIV-1 Protease" <u>Biochem. Biophys. Res. Commun.</u> 241(2):275-280
	38.	Nicolaou et al., "Combinatorial Synthesis Through Disulfide Exchange: Discovery of Potent Psammaplin A Type Antibacterial Agents Active against Methicillin-Resistant Staphylociccus Aureus (MRSA)" Chem. Bur. J. 7(19):4280-4295 (2001)
	39.	Nicolaou et al., "Synthesis and Biological Evaluation of Vancomycin Dimers with Potent Activity against VANCOMYCIN-Resistant Bactewria: Target-Accelarated Combinatorial Synthesis" Chem Eur. J. 7(17):2824-2843 (2001)
	40.	Pollack, S. J. et al., "introduction of Nucelophines and Spectotroscopic Probes into Antibody Combining Sites" Science 242:1038-1040 (1988)
	41.	Ramstrom and Lehn, "In Situ Generation and Screening of a Dynamic Combinatorial Carbohydrate Library against Concanavalin A" ChemBioChem 1:41-48 (2000)
	42.	Sannes-Lowery et al., Trends Anal. Chem 19(8):481-491 (2000)
	43.	Shuker et al., "Discovering High-Affinity Ligands for Proteins: SAR by NMR" Science 274 (5292):1531 (Nov. 1996)
	44.	Stanojevic and Verdine, "Deconstruction of GCN4/GCRE into a monomeric peptide-DNA complex" Nature Structural Biology 2(6):450-457 (June 6, 1995)
-	45.	Thompson et al., "Design of potent and selective human cathepsin K inhibitors that span the active site". Proc. Natl. Acad. Sci USA 94:14249014254 (1997)
	46.	Wetterau et al., "An MTP Inhibitor That Normalizes Atherogenic Lipprotein Levels in WHHL Rabbists" Science 282:751-754 (October 23, 1998)
	47.	Woodcroft et al., "N-Aralkylated derivatives of 1-aminobenzotriazole as isozyme-selective mechanism-based inhibitors of guinea pig hepatic cytochrome P-450 dependent monooxygenase activity" Can J. Physiol. Pharmacol. 68(9):1278-1285 (1990)
4	48.	Zhang et al., "Covalent Modification and Active Site-Directed Inactivation of a low Molecular Weight Phosphotyrosyl Protein Phosphatase" Biochemistry 31(6):1701-1711 (1992)

W:\DOCS\GRD\GRD-5383.DOC 050201

	<u>/</u>		<i>i</i> ,							
EXAMINER	n 4	DATE CONSIDERED	6/1/04							
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.										